CN1699407A - Process for separating and purifying polypeptide prepared by chemical synthesis - Google Patents
Process for separating and purifying polypeptide prepared by chemical synthesis Download PDFInfo
- Publication number
- CN1699407A CN1699407A CN200510040104.6A CN200510040104A CN1699407A CN 1699407 A CN1699407 A CN 1699407A CN 200510040104 A CN200510040104 A CN 200510040104A CN 1699407 A CN1699407 A CN 1699407A
- Authority
- CN
- China
- Prior art keywords
- separation
- organic
- chemically synthesized
- acetate buffer
- ion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 62
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 43
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title claims abstract description 18
- 230000008569 process Effects 0.000 title abstract description 4
- 238000003786 synthesis reaction Methods 0.000 title abstract description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000007790 solid phase Substances 0.000 claims abstract description 5
- 238000000926 separation method Methods 0.000 claims description 37
- 239000008351 acetate buffer Substances 0.000 claims description 26
- 239000012071 phase Substances 0.000 claims description 24
- 238000000746 purification Methods 0.000 claims description 24
- 239000000945 filler Substances 0.000 claims description 20
- 238000004255 ion exchange chromatography Methods 0.000 claims description 16
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical class [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 12
- 238000013375 chromatographic separation Methods 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 8
- 238000004949 mass spectrometry Methods 0.000 claims description 7
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims description 7
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 238000005374 membrane filtration Methods 0.000 claims description 4
- 230000010355 oscillation Effects 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- -1 sulfopropyl Chemical group 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000010647 peptide synthesis reaction Methods 0.000 claims 1
- 238000010828 elution Methods 0.000 abstract description 7
- 238000005342 ion exchange Methods 0.000 abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 230000002194 synthesizing effect Effects 0.000 abstract description 2
- 238000004090 dissolution Methods 0.000 abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 238000005070 sampling Methods 0.000 abstract 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000007501 Thymosin Human genes 0.000 description 3
- 108010046075 Thymosin Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000001641 gel filtration chromatography Methods 0.000 description 3
- 150000002500 ions Chemical group 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000012492 regenerant Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000012766 organic filler Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 101150051821 era gene Proteins 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
The invention provides a process for separating and purifying polypeptide prepared by chemical synthesis comprising, synthesizing polypeptides by means of solid phase polypeptides synthesis, charging pure water into the obtained crude peptides, maintaining the temperature at 20-40 deg. C, supersonic wave oscillating 10-30 minutes for dissolution, charging N,N'-dimethyl formamide (DMF) by the ratio of 1:1 for aiding dissolution, filtering with 0.22um film, obtaining clarified solution, passing the crude peptides solution through ion exchange column, low pressure organic chromatographic column, acetate cushion system and acetic acid / ethanol cushion system for chromatographic column balancing, sampling, adsorbing and elution, thus obtaining polypeptides product with high purity.
Description
Technical field
The present invention relates to the separation purification method of chemically synthesized polypeptide, belong to the biological products manufacture field.
Background technology
Along with finishing of the Human Genome Project and carrying out of functional proteomics research, indicate that the mankind have entered brand-new epoch---back era gene.These have discovered varied biological activity protein and polypeptide, have to promote immunity system, pharmacologic action such as antibiotic, anti-lipid to be worth.The consequent is the develop rapidly of polypeptide drugs, and the research report of Datamonitor company shows that the annual growth of polypeptide protein class medicine reaches 19%, shows that it has become a big focus of field of medicaments.
Polypeptide is because molecular weight is little as medicine, easy synthetic, and it is low to have a cost, high specificity, side effect is low, non-immunogenicity, advantage such as more safe and reliable.There is not the pyrogen problem in artificial synthetic polypeptide purity height in addition.
Artificial synthetic polypeptide is mainly based on solid phase synthesis, and characteristics are that synthesis step is oversimplified, and can access high purity peptide class product simultaneously.Simultaneously, also there are some shortcomings in solid phase synthesis, and the synthetic polypeptide is the low thick product of a kind of purity, must just can obtain high purity product through purifying.All the time, the separation and purification problem is the biggest obstacle in the chemically synthesized polypeptide, its major cause:
1, the side reaction peptide that causes because of various side reactions in synthetic polypeptide process, racemization problem etc.;
2, in the deprotection process, since protecting group residual, the impurity that the fracture of peptide bond, alkylation etc. cause.
The molecular structure of impurity is very similar to target polypeptides, the two or have the difference of some positions amino-acid residue, or fine distinction only on a certain amino-acid residue side chain a certain group whether exist or the like.Because impurity and target polypeptides are so similar on molecular structure and chemical property, have brought difficulty with regard to the separation and purification to polypeptide.
The separation method commonly used of chemically synthesized polypeptide has three kinds: gel filtration chromatography, ion-exchange chromatography, RPLC.The advantage of gel filtration chromatography is the medium neutral, do not have an effect with target molecule, and the separation condition gentleness, the work molecular weight ranges is wide; Its shortcoming is to structural similitude, and what molecular weight was approaching can't be separated, so gel filtration chromatography is used for just separating and the desalination operation more.Ion-exchange chromatography have resolving power height, separation capacity big, be easy to characteristics such as amplification, its defective is and the discrepant polypeptide of electric charge can only be separated, and can't distinguish for the analogue of no charge differences.RPLC (RP-HPLC) just in time addresses this problem.RP-HPLC is the hydrophilic and hydrophobic difference according to polypeptide and analogue thereof, and they are separated; But it has the birth defect that self can't overcome: be difficult for mass-producing, separation costs is too high.Major cause is that carrier requires high, and cost own is big because the reverse phase filler loading is low.Therefore, when scale was amplified, support equipment precision prescribed height, volume was big, investment is big.The present world main chemically synthesized polypeptide company, as: Bachem company, Novabiochem company, American Peptide company etc., its main preparation separation purification method is exactly a RPLC.The main dependence on import of the separating medium of domestic chemically synthesized polypeptide all need spend a large amount of foreign exchanges and be used to buy this type of separating medium every year.Simultaneously, supporting with it equipment claimed high precision, standard such as high pressure resistant, these have constituted one of high major reason of chemically synthesized polypeptide cost.
Summary of the invention
The separation purification method that the purpose of this invention is to provide a kind of chemically synthesized polypeptide, set up polypeptide splitting die blocking technology, promptly finishing ion-exchange with the gel ion-exchange chromatography separates, at first, substitute reverse-phase chromatography with the low pressure organic filler again, realize the low cost of its separating medium according to the different in addition separation and purification of target polypeptides with the electric charge of impurity, reduce high pressure requirement again to equipment, realize the high-efficiency and low-cost isolated polypeptide, after separating through modularization, the yield of polypeptide can reach more than 90%.
Purpose of the present invention can reach by following measure:
Wherein related proportion of raw material is mass ratio except that specified otherwise.
The separation purification method of chemically synthesized polypeptide:
1. utilize the synthetic thick peptide of synthetic (SPPS) method of solid-phase polypeptide, with the thick peptide that obtains (till dissolving) adding pure water in varing proportions, temperature remains on 20～40 ℃, dissolves in 10～30 minutes with ultra-sonic oscillation; If any insolubles, add N with 1: 1 (m/v), N '-dimethyl formamide (DMF) helps dissolving.After the dissolving, membrane filtration obtains settled solution, obtains the thick peptide solution of small peptide, successively carries out the separation and purification of ion-exchange chromatography separation module and the organic chromatographic separation module of low pressure again;
2. ion-exchange chromatography separation module, the separation and purification condition:
Ion exchange column: the ion-exchange chromatography filler is diethylamine ethyl gel filler (DEAE), QAE gel filler (QAE), sulfonic group gel filler (SA), sulfopropyl gel filler (SP) or carboxymethyl gel filler (CM), particle diameter 50～150 μ m;
Moving phase: A:0.1～0.8 mol acetate buffer pH=3～7;
B:0.1～1.0 mol sodium-chlor/acetate buffer pH=3～7;
Flow velocity: 5～10 ml/min;
Gradient: through 20～60 minutes moving phase by 0.1～0.8 mol acetate buffer pH=3～7 to 0.1～1.0 mol sodium-chlor/acetate buffer pH=3～7;
3. the operation steps of ion-exchange chromatography:
I chromatographic column balance: 0.1～0.8 mol acetate buffer pH=3～7, balance is till the baseline stability;
The II sample introduction;
III absorption: 0.1～0.8 mol acetate buffer pH=3～7, treat after the sample penetration steady to baseline;
The IV wash-out: 0.1～1.0 mol sodium-chlor/acetate buffer pH=3～7, linear gradient elution, and collect corresponding component;
V cleans and regeneration: 2 mol sodium-chlor clean, and are steady to baseline; 1 mol sodium hydroxide regenerant ions exchange column; Last pure water is washed till neutrality.
4. with resulting each component, through mass spectroscopy, judge target product place component, it is pure then the target product component to be carried out the organic chromatographic separation of low pressure;
5. the organic chromatographic separation module of low pressure, the separation and purification condition:
Organic chromatographic column: organic chromatograph packing material is organic hydrophobic chromatographic stuffing of organic reverse-phase chromatography filler of MKF-RP series or MKF-PHEMH series, MKF-ETHMH series, particle diameter 5～20 μ m;
Moving phase: A:0.2～2% acetum;
B:0.2～2% acetic acid/ethanolic soln;
Flow velocity: 10～60 ml/min;
Gradient: through 20～60 minutes moving phase by 0.2～2% acetum to 0.2～2% acetic acid/ethanolic soln;
6. the organic stratographic operation steps of low pressure:
I chromatographic column balance: 0.2～2% acetum, balance is till the baseline stability;
The II sample introduction;
The III wash-out: moving phase is by 0.2～2% acetum to 0.2～2% acetic acid/ethanolic soln, linear gradient elution, and collect corresponding component;
IV cleans: 5% acetonitrile/water solution cleans, and is steady to baseline;
V preserves chromatographic column: 100% acetonitrile is preserved chromatographic column.
7. each is collected component, the mass spectroscopy target product, lyophilize then obtains the polypeptide finished product.
The present invention has following advantage compared to existing technology:
1, is easy to technology and amplifies, can prepare by the linear amplification from lab scale to pilot scale;
2, adopt the low pressure organic filler, avoid using conventional anti-phase C18 filler, cost first mate degree reduces;
3, realize the low cost of separation means, the Separation and Recovery rate reaches more than 90%;
4, use ethanol as organic solvent, avoid organic toxicity dissolubilities such as acetonitrile, methyl alcohol, further reduce the purifying cost;
5, the chromatographic separation and purification technology of the present invention's employing, no phase transformation takes place, and no thermal source imports, and does not change pH value of solution value and ionic strength, has guaranteed the high purity of product;
6, whole technology does not have three wastes generation, belongs to environmental protection technology, and its product is safe and reliable.
Embodiment
By embodiment the present invention is carried out concrete description; be necessary to be that following examples only are used for the present invention is further described in this statement; but can not be interpreted as limiting the scope of the invention; the person skilled in the art in this field can make some nonessential improvement and adjustment according to the content of the invention described above, uses to do him.
Embodiment 1
The separation and purification of solid phase synthesis thymopeptide-5
1. utilize solid phase technique to synthesize the thick peptide of thymopeptide-5, the thick peptide that obtains is added pure water with 1: 5 ratio, temperature remains on 25 ℃, dissolves in 15 minutes with ultra-sonic oscillation; After the dissolving, the membrane filtration with 0.22 μ m obtains settled solution.Obtain the thick peptide solution of small peptide;
2. ion-exchange chromatography separation module, the separation and purification condition:
Ion exchange column: sulfopropyl gel filler (SP), particle diameter 90 μ m;
Moving phase: A:0.1～0.8 mol acetate buffer (pH=3～7);
B:0.1～1.0 mol sodium-chlor/acetate buffers (pH=3～7);
Flow velocity: 5～10 ml/min;
Gradient: through 20～60 minutes moving phase by 0.1～0.8 mol acetate buffer (pH=3～7) to 0.1～1.0 mol sodium-chlor/acetate buffer (pH=3～7);
Detect: 220nm
3. the operation steps of ion-exchange chromatography:
I chromatographic column balance: 0.1～0.8 mol acetate buffer (pH=3～7), balance is till the baseline stability;
The II sample introduction;
III absorption: 0.1～0.8 mol acetate buffer (pH=3～7), treat after the sample penetration steady to baseline;
The IV wash-out: 0.1～1.0 mol sodium-chlor/acetate buffer (pH=3～7), linear gradient elution, and collect corresponding component;
V cleans and regeneration: 2 mol sodium-chlor clean, and are steady to baseline; 1 mol sodium hydroxide regenerant ions exchange column; Last pure water is washed till neutrality.
4. with resulting each component, through mass spectroscopy, judge target product place component, it is pure then the target product component to be carried out the organic chromatographic separation of low pressure;
5. the organic chromatographic separation module of low pressure, the separation and purification condition:
Organic chromatographic column: organic reverse-phase chromatography filler of MKF-RP series, particle diameter 10 μ m;
Moving phase: A:0.2～2% acetum;
B:0.2～2% acetic acid/ethanolic soln;
Flow velocity: 10～60 ml/min;
Gradient: through 20～60 minutes moving phase by 0.2～2% acetum to 0.2～2% acetic acid/ethanolic soln;
Detect: 220nm
6. the organic stratographic operation steps of low pressure:
I chromatographic column balance: 0.2～2% acetum, balance is till the baseline stability;
The II sample introduction;
The III wash-out: moving phase is by 0.2～2% acetum to 0.2～2% acetic acid/ethanolic soln, linear gradient elution, and collect corresponding component;
IV cleans: 5% acetonitrile/water solution cleans, and is steady to baseline;
V preserves chromatographic column: 100% acetonitrile is preserved chromatographic column.
7. each is collected component, the mass spectroscopy target product, lyophilize then obtains the thymopeptide-5 finished product, and its purity reaches 99%.
Embodiment 2
The separation and purification of solid phase synthesis thymosin
1. utilize solid phase technique synthesizing thymosins α 1 thick peptide, the thick peptide that obtains is added pure water (18.2M Ω) with 1: 10 ratio, temperature remains on 30 ℃, dissolves in 25 minutes with ultra-sonic oscillation; Add N with 1: 1 (m/v), N '-dimethyl formamide (DMF) helps dissolving, and after the dissolving, the membrane filtration with 0.22 μ m obtains settled solution.Obtain the thick peptide solution of small peptide;
2. ion-exchange chromatography separation module, the separation and purification condition:
Ion exchange column: diethylamine ethyl gel filler (DEAE), particle diameter 120 μ m;
Moving phase: A:0.1～0.8 mol acetate buffer (pH=3～7);
B:0.1～1.0 mol sodium-chlor/acetate buffers (pH=3～7);
Flow velocity: 5～10 ml/min;
Gradient: through 20～60 minutes moving phase by 0.1～0.8 mol acetate buffer (pH=3～7) to 0.1～1.0
Mol sodium-chlor/acetate buffer (pH=3～7);
Detect: 220nm
3. the operation steps of ion-exchange chromatography:
I chromatographic column balance: 0.1～0.8 mol acetate buffer (pH=3～7), balance is till the baseline stability;
The II sample introduction;
III absorption: 0.1～0.8 mol acetate buffer (pH=3～7), treat after the sample penetration steady to baseline;
The IV wash-out: 0.1～1.0 mol sodium-chlor/acetate buffer (pH=3～7), linear gradient elution, and collect corresponding component;
V cleans and regeneration: 2 mol sodium-chlor clean, and are steady to baseline; 1 mol sodium hydroxide regenerant ions exchange column; Last pure water is washed till neutrality.
4. with resulting each component, through mass spectroscopy, judge target product place component, it is pure then the target product component to be carried out the organic chromatographic separation of low pressure;
5. the organic chromatographic separation module of low pressure, the separation and purification condition:
Organic chromatographic column: organic hydrophobic chromatographic stuffing of MKF-PHEMH series, MKF-ETHMH series, particle diameter 10 μ m;
Moving phase: A:0.2～2% acetum;
B:0.2～2% acetic acid/ethanolic soln;
Flow velocity: 10～60 ml/min;
Gradient: through 20～60 minutes moving phase by 0.2～2% acetum to 0.2～2% acetic acid/ethanolic soln;
Detect: 220nm
6. the organic stratographic operation steps of low pressure:
I chromatographic column balance: 0.2～2% acetum, balance is till the baseline stability;
The II sample introduction;
The III wash-out: moving phase is by 0.2～2% acetum to 0.2～2% acetic acid/ethanolic soln, linear gradient elution, and collect corresponding component;
IV cleans: 5% acetonitrile/water solution cleans, and is steady to baseline;
V preserves chromatographic column: 100% acetonitrile is preserved chromatographic column.
7. each is collected component, the mass spectroscopy target product, lyophilize then obtains the thymosin finished product, and its purity reaches 97%.
Claims (6)
1, a kind of separation purification method of chemically synthesized polypeptide is characterized in that:
1. utilize solid-phase peptide synthesis to synthesize polypeptide, the thick peptide that obtains is added pure water, temperature remains on 20～40 ℃, dissolves in 10～30 minutes with ultra-sonic oscillation; After the dissolving, membrane filtration obtains settled solution, obtains the thick peptide solution of small peptide, successively carries out the separation and purification of ion-exchange chromatography separation module and the organic chromatographic separation module of low pressure again;
2. ion-exchange chromatography separation module, adopting particle diameter is 50～150 μ m ion-exchange chromatography fillers; Moving phase is acetate buffer and sodium-chlor/acetate salt buffer liquid system; Flow velocity 5～10 ml/min;
3. the organic chromatographic separation module of low pressure, adopting particle diameter is the organic chromatograph packing materials of 5～20 μ m; Moving phase is acetum and acetic acid/ethanolic soln system; Flow velocity is 10～60 ml/min;
4. each is collected component, the mass spectroscopy target product, lyophilize then obtains the polypeptide finished product.
2, the separation purification method of chemically synthesized polypeptide according to claim 1 is characterized in that adding N with 1: 1, and N '-dimethyl formamide helps the thick peptide of dissolving.
3, the separation purification method of chemically synthesized polypeptide according to claim 1 is characterized in that described ion-exchange chromatography filler is diethylamine ethyl gel filler, QAE gel filler, sulfonic group gel filler, sulfopropyl gel filler or carboxymethyl gel filler.
4, the separation purification method of chemically synthesized polypeptide according to claim 1 is characterized in that the organic chromatograph packing material of described low pressure is organic hydrophobic chromatographic stuffing of organic reverse-phase chromatography filler of MKF-RP series or MKF-PHEMH series, MKF-ETHMH series.
5, the separation purification method of chemically synthesized polypeptide according to claim 1 is characterized in that the ion-exchange chromatography separation module:
Moving phase: A:0.1～0.8 mol acetate buffer pH=3～7;
B:0.1～1.0 mol sodium-chlor/acetate buffer pH=3～7;
Gradient: through 20～60 minutes moving phase by 0.1～0.8 mol acetate buffer pH=3～7 to 0.1～1.0 mol sodium-chlor/acetate buffer pH=3～7.
6, the separation purification method of chemically synthesized polypeptide according to claim 1 is characterized in that the organic chromatographic separation module of low pressure:
Moving phase: A:0.2～2% acetum;
B:0.2～2% acetic acid/ethanolic soln;
Gradient: through 20～60 minutes moving phase by 0.2～2% acetum to 0.2～2% acetic acid/ethanolic soln.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100401046A CN1319986C (en) | 2005-05-20 | 2005-05-20 | Process for separating and purifying polypeptide prepared by chemical synthesis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100401046A CN1319986C (en) | 2005-05-20 | 2005-05-20 | Process for separating and purifying polypeptide prepared by chemical synthesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1699407A true CN1699407A (en) | 2005-11-23 |
| CN1319986C CN1319986C (en) | 2007-06-06 |
Family
ID=35475671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100401046A Expired - Fee Related CN1319986C (en) | 2005-05-20 | 2005-05-20 | Process for separating and purifying polypeptide prepared by chemical synthesis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1319986C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116162124A (en) * | 2023-04-21 | 2023-05-26 | 吉尔生化（上海）有限公司 | Preparation method of continuous glutamine polypeptide |
-
2005
- 2005-05-20 CN CNB2005100401046A patent/CN1319986C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116162124A (en) * | 2023-04-21 | 2023-05-26 | 吉尔生化（上海）有限公司 | Preparation method of continuous glutamine polypeptide |
| CN116162124B (en) * | 2023-04-21 | 2023-06-30 | 吉尔生化（上海）有限公司 | Preparation method of continuous glutamine polypeptide |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1319986C (en) | 2007-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110627897B (en) | Active peptide for promoting osteoblast proliferation and application thereof | |
| CN105566452B (en) | Antibacterial peptide with cyclic structure and preparation method and application thereof | |
| CN110283252B (en) | Pig-derived hybrid antibacterial peptide PP-1 and preparation method and application thereof | |
| CN1606568A (en) | Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor | |
| CN102408468B (en) | Argatroban compound and preparation method thereof | |
| CN105906709A (en) | Alaska Pollock fish skin active oligopeptides as well as synthesis method and application thereof | |
| CN109369783B (en) | Polypeptide RDP1, and purification method and application thereof | |
| CN1319986C (en) | Process for separating and purifying polypeptide prepared by chemical synthesis | |
| CN1254496C (en) | Method of preparing branched polyethylene glycol | |
| CN101041818A (en) | Method for recombinant production of pancreatic glucagons sample peptide-2 | |
| CN1865279A (en) | Solid phase polypeptide synthesis preparation method for thymopoietin pentapeptide | |
| CN1749274A (en) | Separating and purifying method for new recombinant human interferon alpha2b | |
| CN105017401B (en) | Purification method of ziconotide | |
| CN1163515C (en) | New affinity chromatography medium and purification method for cobra neurotoxin | |
| CN1990862A (en) | Production method of recombined human alpha1-thymus peptide and preparation thereof | |
| CN1154658C (en) | Process for the purification of glycoproteins like erythropoietin | |
| WO2021017793A1 (en) | Method for preparing chemically synthesized acidic polypeptide | |
| CN104447977A (en) | Purification production method for recombinant human bone morphogenetic protein-2 | |
| CN1226418C (en) | Natural active protein and peptide separating and purifying process | |
| CN101045923A (en) | Process of producing interleukin analog | |
| CN1490333A (en) | Insulinotropic peptide and its use | |
| CN102241749B (en) | Solid-phase synthesis method of vMIP-II (viral macrophage inflammatory protein-II) protein | |
| CN1294256C (en) | Gene-expressed human tissue kallikrein protein separating and purifying method | |
| CN103130872A (en) | Adsorbent, solid phase carrier and purification method | |
| CN1876176A (en) | Omega-conotoxin M VII A mutant and its preparation and uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070606 Termination date: 20100520 |